There are 2949 resources available
1485P - Response prediction using NanoString nCounter technology and NGS panel sequencing in neoadjuvant chemotherapy in patients with esophagogastric adenocarcinoma
Presenter: Severin Daum
Session: E-Poster Display
Resources:
Abstract
1486P - The impact of CT-based body composition parameters on survival outcomes in Western patients (pts) with resected gastric and gastroesophageal junction adenocarcinoma (GEA)
Presenter: Massimiliano Salati
Session: E-Poster Display
Resources:
Abstract
1487P - Prognostic impact of thyroid hormone status in resectable gastroesophageal cancer
Presenter: Hannah Puhr
Session: E-Poster Display
Resources:
Abstract
1488P - A prognostic biomarker study in patients who underwent surgery or received chemoradiotherapy for clinical stage I esophageal squamous cell carcinoma
Presenter: Kotoe Oshima
Session: E-Poster Display
Resources:
Abstract
1489P - Liquid biopsy forecasted disease progression and indicated therapeutic improvement for gastric cancer patients receiving HER2-targeted regimen
Presenter: Cheng Zhang
Session: E-Poster Display
Resources:
Abstract
1490P - Evaluation of circulating tumor cells in esophageal carcinoma patients who received chemotherapy or neoadjuvant chemotherapy
Presenter: Matsumoto Takuro
Session: E-Poster Display
Resources:
Abstract
1491P - Bespoke circulating tumor DNA assay for the detection of minimal residual disease in esophageal adenocarcinoma patients
Presenter: Emma Ococks
Session: E-Poster Display
Resources:
Abstract
1492P - Investigation of DNA damage repair mutations and correlation with immunogenic biomarker in Chinese esophageal squamous cell carcinoma patients
Presenter: Wenyi Liu
Session: E-Poster Display
Resources:
Abstract
1493P - An integrated analysis of gene expression profile and chromosomal aberrations highlighted the oxidative stress role in anti-HER2 drug-resistant gastric cancer models
Presenter: Valentina Gambardella
Session: E-Poster Display
Resources:
Abstract
1494P - Updated safety data of the DANTE trial: Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma - A randomized, open-label phase II trial of the German Gastric Group at the AIO and SAKK
Presenter: Salah-Eddin Al-Batran
Session: E-Poster Display
Resources:
Abstract